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2. Abstract. 
 
 
Cardiovascular diseases and in particular cardiac arrhythmias as ventricular fibrillation 
have a leading role in mortality in the developed countries. Accordingly, cardiac arrhythmias 
represent a major area of cardiovascular research. Drug therapy has traditionally been the 
major type of treatment for both ventricular and supraventricular arrhythmias. In spite of the 
important advances in cardiology, the pharmacological treatment of cardiac arrhythmias 
remained empiric to a large extent because of our incomplete understanding the mechanisms 
by which antiarrhythmic drugs prevent/suppress, or unfortunately even induce arrhythmias. 
Therefore, in order to develop new more effective agents with less proarrhythmic potency, it 
is important to understand the mechanism of action of antiarrhythmic drugs at the organ, 
tissue, cellular and also subcellular levels. Based on the promising results of recent cellular 
pathophysiological and pharmacological investigations in the present PhD thesis, we have 
focused our research especially on pharmacological modulation of repolarizing potassium and 
sodium-calcium exchanger (NCX) currents as key elements in generating arrhythmias. 
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The aims of the present study were: 
a) To analyse the contribution of different auxiliary proteins to the altered expression of 
genes for Kir2.x ion channels in dilated cardiomyopathy. 
b) To investigate and compare the effects of several newly synthetized NCX blockers on 
several mammalian hearts. Selection of a lead NCX blocker compound for further analysis. 
c) To investigate the electrophysiological effects of the lead compound GYKB-6635, a 
newly synthetized specific NCX inhibitor, on the NCX, L-type Ca2+ and several potassium 
currents and on the triggered arrhythmias (formation of delayed afterdepolarizations). 
 
Our results demonstrate: 
1) The endogenous Kir2.x channels associate with SAP97 forming signalling complexes. In 
DCM, the levels of Kir2.1 and Kir2.3 were upregulated but those of Kir2.2 channels were 
down-regulated. These adaptations could offer a new aspect for the explanation of the 
generally observed physiological and molecular alterations found in DCM. The SAP97 and 
Kir2.x ion channels may be novel target molecules in the diagnosis and effective treatment 
of cardiomyopathy. 
2) We have demonstrated in vitro the potential inhibitory NCX blocking effect and of several 
carbocyclic nucleoside analogues (CNA) having different structures than from already 
known selective NCX blockers.  
3) GYKB-6635 is the first compound that inhibits forward and reverse mode of the NCX 
current at submicromolar concentrations, and does not affect any other important 
transmembrane mechanisms involved in Ca2+-homeostasis and cardiac repolarization. In 
addition, GYKB-6635 compound proved to be effective against DAD related arrhythmias, 
since in isolated Langendorff perfused heart experiments prevented disturbances of the 
heart rhythm in ouabain induced arrhythmias in guinea pigs. 
4)  In conclusion, in the present study we describe a new and highly selective NCX inhibitor 
compound that may be suitable to test whether NCX blockade offers beneficial 
antiarrhythmic effects.  
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3. Introduction 
 
 
Cardiovascular diseases, and in particular, cardiac arrhythmias, such as ventricular 
fibrillation have a leading role in mortality in developed countries. The most serious 
ventricular arrhythmia – ventricular fibrillation – causes the death of more than 3.000.000 
people all over the world and 300.000 – 350.000 people in the USA and Europe annually, 
which statistically means that one person dies every minute on each continent. In the majority 
of the cases sudden cardiac death occurs when victims are not in hospital, consequently, 
survival probability is very low. Most frequently (50%) the background of the on-the-spot 
diagnosed circulation collapse is ventricular tachycardia /fibrillation/. Sudden cardiac death 
(SCD) is often the very first sign of the symptom-free cardiovascular disease. SCD is a 
complex national health problem affecting families and having significant social and 
economic consequences, since usually it is the head of the family, a seemingly healthy man, 
who dies tragically. Accordingly, cardiac arrhythmias represent a major area of 
cardiovascular research. One of the main goals of pharmacological research is to develop a 
safe ventricular antiarrhythmic drug that can be applied either in acute cases or for treating 
postinfarction patients.  
In the past, drug treatment of cardiac arrhythmias has proven difficult, both because of 
inadequate effectiveness and a risk of serious complications. In spite of the important 
advances in cardiology, the pharmacological treatment of cardiac arrhythmias remained 
empiric to a large extent because of our incomplete understanding of either physiological and 
pathophysiological processes underlying the cardiac rhythm disturbances and the mechanisms 
by which antiarrhythmic drugs prevent, suppress, and in some cases also induce, arrhythmias. 
Therefore, in order to develop new more effective agents with less proarrhythmic potency, it 
is important to understand the mechanism of action of antiarrhythmic drugs at the organ, 
tissue, cellular and also subcellular levels.  
 Dilated cardiomyopathy (DCM) is a myocardial disorder characterized by left 
ventricular dilation and systolic dysfunction often leading to progressive heart failure, 
arrhythmias and premature death. DCM is associated with increased APD, decreased resting 
membrane potential (RMP), and the whole-cell current slope conductance in cells of DCM is 
smaller than that for donor or ischemic cardiomyopathy. As a chronic multifactorial disease, 
DCM is likely to affect multiple clusters of genes. Marked alterations were observed in the 
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characteristics of the inward rectifier potassium current (IK1), but not of the sodium current 
(INa) in ventricular myocytes of DCM patients as compared to donors.. The IK1 current plays a 
major role for maintaining the cellular resting membrane potential and it is involved in the 
consequences of DCM such as in the arrhythmogenesis of coronary artery disease and 
ventricular arrhythmias with sudden cardiac death. However, the molecular mechanisms 
underlying these alterations of IK1 are still largely unknown.  
 One arrhythmogenic factor that can result in ventricular arrhythmias occurring in 
myocardial ischaemia or poisoning with digitalis is delayed afterdepolarization (DAD), which 
arises in heart muscle cells following Ca2+ overload. Reducing the incidence of these trigger 
mechanism, the delayed afterdepolarization (DAD) or their pharmacological blockade would 
be extremely desirable from a clinical point of view. 
 Among several other currents and transporters, maintenance of the Ca2+ homeostasis 
in the myocardium is mainly regulated by the sodium-calcium exchanger (NCX). It is known 
that NCX, at the forward mode, extrudes Ca2+ from the cell to the extracellular space during 
diastole, at relatively low free cytoplasmic Ca2+ concentration and negative transmembrane 
potential. Since the extrusion of one Ca2+ is coupled with 3 Na+ entering the cell, during the 
forward mode of the NCX net inward current is carried, which can cause substantial 
depolarization leading to early (EAD) and delayed (DAD) after-depolarizations, especially 
when intracellular Ca2+ is elevated. Neither our current knowledge on NCX structure/function 
relationship is complete, nor the selectivity of current NCX modulators are satisfactory  
especially in conditions where potassium conductance is decreased, such as heart failure 
Therefore, one may speculate that specific blockers of NCX could be potential 
antiarrhythmics in dysrhythmias related to Ca2+ overload. This hypothesis could not be 
directly tested since the available NCX inhibitors. This unmet need provides a rationale for 
pharmacologists and medicinal chemists to get more involved in NCX research by designing 
and developing novel compounds to modulate NCX activity. 
Therefore, in the present study carbocyclic nucleoside analogues (CNA) as potential 
novel selective inhibitors of NCX current and their effect on DAD related and ischemia-
-reperfusion (IR) induced cardiac arrhythmias are investigated. A particular attention was 
played to investigate the effects of the CNA derivate and  highly selective novel NCX 
inhibitor GYKB-6635 [(4-amino-1-[((1R,2S,3S,5R)-2,3-dihydroxy-6,6-dimethylbicyclo[3.1.1] 
heptan-2-yl)methyl]pyrim idin-2(1H)-one) on the NCX current, cardiac ventricular action 
potentials and to determine its antiarrhythmic effects.  
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4. Major specific experimental goals 
 
The main goals of my PhD work was to investigate: (i) the remodelling effect of one 
specific cardiac disease on the repolarization; (ii) the pharmacological modulation of the 
cardiac arrhythmias by affecting a novel pharmacological target. Thereby the specific goals 
were as follows:  
a) To analyse the contribution of different auxiliary proteins to the altered expression of 
genes for Kir2.x ion channels in dilated cardiomyopathy. 
b) To investigate and compare the effects of several newly synthetized NCX blockers on 
several mammalian hearts. Selection of a lead NCX blocker compound for further analysis. 
c) To investigate the electrophysiological effects of the lead compound GYKB-6635, a 
newly synthetized specific NCX inhibitor, on the NCX, L-type Ca2+ and several potassium 
currents and on the triggered arrhythmias (formation of delayed afterdepolarizations). 
 
5. Methods 
 
Experiments were carried out in ventricular myocytes enzymatically isolated from dog 
and rabbit hearts and from undiseased human cardiac ventricular preparations. The protocols 
used on guinea pig and dog heart preparations were approved by the Review Board of the 
Department of Animal Health and Food Control of the Ministry of Agriculture and Rural 
Development, Hungary (XIII./1211/2012). The experimental protocols used on human 
myocytes complied with the Declaration of World Medical Association proclaimed in 
Helsinki and were approved by the University of Szeged and National Scientific and Research 
Ethical Review Boards (No. 51-57/1997 OEj and 4991-0/2010-1018EKU (339/PI/010.)). 
The in vitro electrophysiological (standard microelectrode and patch-clamp 
techniques) measurements were performed in dog and human cardiac preparations. 
Langendorff perfused guinea hearts were used for ouabain induced arrhythmia studies. 
Human Kir2.x protein level and mRNA level expressions and immunofluorescence 
investigations were performed by applying several molecular cardiology methods including 
Western-blot and qPCR techniques and confocal microscopy, respectively.  
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6. Results 
 
6.1. The investigation of the expression of genes for Kir ion channel isoforms in dilated 
cardiomyopathy 
 
 
Dilated cardiomyopathy (DCM) is a multi-factorial disease characterized by left 
ventricular dilation that is associated with systolic dysfunction and increased action potential 
duration. The Kir2.x K+ channels (encoded by KCNJ genes) regulate the inward rectifier 
current (IK1) contributing to the final repolarization in cardiac muscle. Here, we describe the 
transitions in the gene expression profiles of four KCNJs, from non-diseased to dilated 
cardiomyopathic human hearts.  
Cardiac left ventricular samples were obtained from 12 hearts of DCM patients and 
compared with those of 12 undiseased donors.  We observed marked changes in the relative 
mRNA levels of IK1-related genes in the ventricle of DCM patients as compared to controls. 
Thus Kir2.1 and SUR1 mRNA levels increased, while those for Kir6.1 α-subunit and SUR2 
β-subunit were declined relative to undiseased controls. Relative mRNA level for Kir3.4 was 
also reduced in patients, whereas the mRNA levels of Kir3.1 and Kir6.2 did not differ 
between hearts of control and DCM patients. 
Next we performed immunoblotting analysis of protein samples matching the RNA 
sources to reveal if differences in steady state mRNA levels were manifested in protein 
content. As expected, anti-human Kir2.1, Kir2.2, and Kir2.3 antibodies recognized bands of 
55 kDa, 45 kDa and 57 kDa, respectively.  Kir2.1 protein expression was increased in the 
ventricles of DCM hearts confirming thus the mRNA data. Immunoblots were reprobed with 
anti-GAPDH and/or α-actin antiserum and the intensity of immunosignals was then quantified 
by image analysis software relative to GAPDH or α-actin internal controls. The normalized 
protein amount of Kir2.1 isoform was higher (with about 70 %) showing some individual 
variability, while the Kir2.2 isoform was lower (by about 29 %) in DCM compared to control 
hearts. The Kir2.3 protein content, however, did not differ considerably between donor and 
DCM ventricular tissue samples. 
Taken all these data together we may conclude that, qRT-PCR analysis confirmed that 
mRNA expression for Kir2.1 (KCNJ2), Kir2.3 (KCNJ4) and Kir2.4 (KCNJ14) coding genes 
significantly increased (2.26-fold, 1.94-fold and 1.6-fold, respectively), while mRNA level 
for Kir2.2 (KCNJ12) was reduced to 66% in DCM ventricle versus control. In agreement with 
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RNA data, Western analysis revealed increased Kir2.1 and decreased Kir2.2 protein levels in 
DCM patients, but the Kir2.3 level was not markedly altered as compared to control. 
Considering that SAP97 can associate with Kir2.2 and Kir2.3 isoforms in the heart 
samples, we observed significant changes in Kir2.1 and Kir2.2 mRNA and protein levels, it 
was interesting to check whether mRNA level for SAP97 regulatory protein has also changed 
in DCM. Gene expression for SAP97 was validated by qRT-PCR. The SAP97 mRNA level 
decreased significantly in DCM patients. Furthermore, we observed robust age-dependent 
changes in SAP97 mRNA expression even in donor hearts, when we compared 31 undiseased 
and 17 DCM samples. SAP97 mRNA level decreased about 50% at age of 40 years or higher. 
SAP97 mRNA levels were high at ages between 12-40 years in control cardiac ventricles and 
decreased by 52 % in DCM patients. After 40 years of age, however, the differences in the 
SAP97 mRNA levels diminished between control and DCM hearts.  
Based on the robust changes in Kir2.x and SAP97 mRNA expression in DCM versus 
normal heart, we hypothesized that SAP97 binding to Kir2x isoforms and distribution of their 
complexes might have changed in cardiomyocytes of DCM heart. To address the potential 
differences in the distribution of SAP97-Kir2.x complexes in DCM, we used indirect 
immunofluorescence. Double immunofluorescence showed the colocalization of SAP97 with 
type of Kir2.1 or Kir2.2 isoforms in cardiomyocytes of ventricular tissues in both control and 
DCM hearts. Whereas the distribution of Kir2.1 and SAP97 partially overlapped in the 
intercalated discs of control sections, their colocalization was more obvious in failing human 
ventricle as judged by the number and intensity of merged yellow spots (data not shown).  
During the last decade a few publications have suggested from the altered action 
potential (AP) shape in DCM that the properties of IK1 current could be changed (Koumi et al. 
1995). Therefore, we studied the IK1 current in human cardiomyocytes derived from the heart 
of undiseased donors and DCM patients. We measured IK1 by whole cell patch-clamp 
technique in the isolated ventricular myocytes. At -60 mV IK1 density was moderately lower 
in the undiseased donor cardiomyocytes than in DCM human ventricular myocytes. Steady-
state inward IK1 density was reduced in cells isolated from DCM ventricle compared with 
undiseased myocardium.  
 
6.2. The investigation of several newly synthetized CNA compounds as novel selective 
NCX inhibitors. The selection of GYKB-6635 as lead compound 
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In the present study carbocyclic nucleoside analogues (CNA) as potential novel 
selective inhibitors of NCX current and their effect on DAD related and ischemia-reperfusion 
(IR) induced cardiac arrhythmias are investigated in mammalian hearts. The structures of 
these CNA compounds basically differ from the already known selective NCX blockers, like 
KB-R7943 and SEA-0400 or from ORM-10103.  
The following compounds were synthetized and investigated: GYKB-6635; GYKB-
-6704; GYKB-6707. NCX current was measured by applying the whole cell patch-clamp 
technique. Current was measured as a Ni2+ sensitive current using voltage ramp waveforms 
for the command potential. The effect of various concentrations of the compounds on outward 
NCX current (reverse mode) was calculated at 20 mV, and on inward current (forward mode) 
was determined at -80 mV. Based on these results we conclude that GYKB-6635, GYKB-
-6704 and GYKB-6707 effectively inhibit the NCX current at micromolar concentration 
ranges. The most potent compound seems to be GYKB-6635, therefore this compound has 
been selected for further analysis described in the chapter 3.3. 
 
6.3. Investigation of the cellular electrophysiological and antiarrhythmic effects of 
GYKB-6635 in mammalian hearts 
 
 
The aim on the present investigations was the systematic investigation of the 
carbocyclic nucleoside analogue compound GYKB-6635, as lead highly selective NCX 
blocker compound. The potential antiarrhythmic potency of GYKB-6635 compound was also 
investigated in detail. The results of the experiments showed that 1 µM GYKB-6635 reduced 
by 57 % the reverse NCX current (from 52.5 ±18.5 pA in controls to 22.4 ±11.9 pA after drug 
administration, n=4, p<0.05), while the forward current was reduced by 58 % (from -52.7 ±21 
pA in controls to -21.8 ±12.3 pA after drug administration, n=4, p<0.05). 
This blocking effect was quite selective, because it was shown that, GYKB-6635 even 
at high (10 M) concentration did not influence ICaL, the fast inward sodium current (INa), and 
the four main repolarizing currents, Ito, IK1, IKr and IKs. The selective blocking effect of the 
GYKB-6635 compound proved to be effective against DAD related arrhythmias, since in 
isolated Langendorff perfused heart experiments prevented disturbances of the heart rhythm 
in ouabain induced arrhythmias in guinea pigs. 
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7. Conclusions and potential significance 
 
The conclusions and main findings of the present thesis are as follows: 
 
1) The endogenous Kir2.x channels associate with SAP97 forming signalling complexes. The 
Kir2.1 strongly binds SAP97, and they show co-localization near the T-tubules. In 
undiseased adult ventricle, KCNJ2, KCNJ12 and KCNJ4 (Kir2.1-2.3) genes were 
expressed at high level; while the expression of KCNJ14 (Kir2.4) gene was low. In DCM, 
the levels of Kir2.1 and Kir2.3 were upregulated but those of Kir2.2 channels were down-
regulated. These adaptations could offer a new aspect for the explanation of the generally 
observed physiological and molecular alterations found in DCM. The SAP97 and Kir ion 
channels may be novel target molecules in the diagnosis and effective treatment of 
cardiomyopathy. 
 
2) We have demonstrated in vitro the potential inhibitory NCX blocking effect and of several 
carbocyclic nucleoside analogues (CNA). The structures of these CNA compounds 
basically differ from the already known selective NCX blockers, like KB-R7943, 
SEA0400 and ORM-10103. 
 
3) GYKB-6635 is the first compound that inhibits forward and reverse mode of the NCX 
current at submicromolar concentrations, and does not affect any other important 
transmembrane mechanisms involved in Ca2+-homeostasis and cardiac repolarization. In 
addition GYKB-6635 compound proved to be effective against DAD related arrhythmias, 
since in isolated Langendorff perfused heart experiments prevented disturbances of the 
heart rhythm in ouabain induced arrhythmias in guinea pigs. 
 
4)  We may concluded that GYKB-6653 is a new and highly selective NCX inhibitor 
compound that may be suitable to test whether NCX blockade offers beneficial 
antiarrhythmic effects. Further studies are needed using both in vitro and in vivo methods 
to elucidate the potential therapeutic targets and, in a wider sense, the possible beneficial 
effects of specific NCX inhibition.  
 
  
12 
 
 
 
8. Acknowledgements 
 
I am very grateful to Professor Julius Gy. Papp MD, DSc, academician, for his 
continuous support, his kindness and critical reading of my manuscripts, his inspirational 
comments and constructive criticism were always of help and are greatly appreciated, and to 
Professor András Varró MD, DSc for providing me the opportunity for research as PhD 
student at the Department of Pharmacology and Pharmacotherapy, University of Szeged and 
the helpful discussions were exceptionally useful during my work. 
I am especially thankful to my PhD supervisor Dr. Norbert Jost, for personal guidance 
and for introducing me to the fascinating world of cardiac cellular electrophysiology. I always 
enjoyed his optimistic attitude to the scientific problems. Without his continuous support, 
never-failing interest and eagerness to discuss new ideas, plans and findings throughout these 
years, this PhD study could have hardly come to an end. 
I am indebted to Professor Ferenc Fülöp (Institute of Pharmaceutical Chemistry, 
Faculty of Pharmacy) and his colleagues for the synthesis of the GYKB compounds.  
Dr. Claudia Corici and Zsófia Kohajda are sincerely thanked for excellent 
collaboration during the years, for the many hours of splendid discussions and helpful 
scientific lessons.  
I wish to thank my senior colleagues Dr. László Virág and Dr. András Tóth and my 
other junior (PhD students and postdocs) colleagues, Dr. Károly Acsai András Horváth, 
Dr. Norbert Nagy, Kinga Oravecz and Dr. János Prorok for their continuous support and 
help in my work, for creating a cheerful and social milieu in the laboratory, and to Mrs. 
Zsuzsanna Molnár and Mr. Gábor Girst for their helpful technical assistance.  
 I also wish to thank my parents, to Whom I want to dedicate this thesis, for their 
endless love, trust and support.  
This work was supported by the grants from the Hungarian Scientific Research Fund 
(OTKA NK-104331, NN-109904 and ANN-113273) the National Research Development and 
Innovation Office (K-119992, GINOP-2.3.2-15-2016-00006 and GINOP-2.3.2-15-2016-
00012), the National Office for  Research and Technology – Gábor Baross and Ányos Jedlik 
Programmes (REG-DA-09-2-2009-0115-NCXINHIB and NKFP_07_01-RYT07_AF), HU-
RO Cross-Border Cooperation Programmes (HURO/1001/086/2.2.1_HURO-TWIN) and the 
Hungarian Academy of Sciences.  
 
 
